Show simple item record

dc.contributor.advisor安汉祥
dc.contributor.author马逸涵
dc.date.accessioned2018-12-05T01:50:04Z
dc.date.available2018-12-05T01:50:04Z
dc.date.issued2018-02-28
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/170973
dc.description.abstract肺癌是世界上死亡率和发病率增长最快,对人类健康和生命威胁最大的恶性肿瘤。非小细胞肺癌(NSCLC)含有多种细胞类型,占据新发肺癌患者的85%。吸烟仍是主要危险因素,不断恶化的大气污染也渐渐在肺癌成因中占据一席之地。目前,肺癌的治疗方法是以外科手术为中心,多种治疗方式如放化疗配合的综合治疗。由于大多数非小细胞肺癌患者就诊时便已处于晚期,能手术的患者只占一小部分。目前临床常用的化疗药物副作用较大,收益相对有限。近年来,得益于癌驱动基因的发现与研究,靶向治疗成为了中晚期非小细胞肺癌新的临床治疗方法,代表药物就是酪氨酸激酶抑制剂(TKI)。与化疗相比,TKI主要针对EGFR敏感突变的非小细胞肺癌,临床...
dc.description.abstractLung cancer is the leading cause of cancer related death worldwide. Non-small-cell lung cancer (NSCLC) which consists of heterogeneous classes of tumors represents approximately 85% of all new lung cancer diagnoses. Smoking remains important while air pollution becomes more and more severe. Most patients are diagnosed with advanced-stage for inadequate prevention awareness and unclear symptoms and...
dc.language.isozh_CN
dc.relation.urihttps://catalog.xmu.edu.cn/opac/openlink.php?strText=59637&doctype=ALL&strSearchType=callno
dc.source.urihttps://etd.xmu.edu.cn/detail.asp?serial=60427
dc.subject循环miRNA
dc.subjectmiRNA芯片
dc.subject非小细胞肺癌
dc.subject表皮生长因子受体
dc.subject药物反应
dc.subjectcirculating miRNA
dc.subjectmicroarray
dc.subjectNSCLC
dc.subjectEGFR
dc.subjectresponse
dc.titleDel19与L858R突变非小细胞肺癌患者血浆miRNA表达谱差异及相关机制探索
dc.title.alternativePlasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations
dc.typethesis
dc.date.replied2017-05-15
dc.description.note学位:医学硕士
dc.description.note院系专业:医学院_肿瘤学
dc.description.note学号:24520141153570


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record